Looking at the case of Myriad Genetics, Harvard Business School's Richard Hamermesh proposes that the health care market compete on solutions rather than intellectual property rights.
Looking at the case of Myriad Genetics, Harvard Business School's Richard Hamermesh proposes that the health care market compete on solutions rather than intellectual property rights.
Share this Article
Recommended